Baker McKenzie advised German headquartered AESKU.GROUP on its acquisition of the immunofluorescence assay (IFA) specialist MBL BION, based in Des Plaines Illinois, from MBL International, a subsidiary of JSR Life Sciences. The acquisition secures AESKU.GROUP's position as the leading provider of IFA solutions to clinical laboratories.


A cross-border team of equity capital markets, corporate and healthcare Baker McKenzie lawyers led by partner Berthold Hummel advised AESKU.GROUP on all legal aspects of the transaction.


MBL BION, part of MBL Intl., a subsidiary of JSR Life Sciences, is an American company founded in 1978 that specializes in manufacturing high-quality IFA products for clinical laboratories. The company is FDA-registered and ISO 13485:2016 certified. They are experts in IFA for immunology, virology, and microbiology.


Incorporated by Dr. Torsten Matthias back in 2000, AESKU.GROUP, headquartered in Wendelsheim, Germany, includes AESKU.DIAGNOSTICS, AESKU.SYSTEMS, AESKU.THERAPY, and AESKU.KIPP INSTITUTE, and uses scientific expertise to translate basic research into accurate, reliable, and easy-to-use products. It employs more than 300 employees and has subsidiaries in the USA, China, England, Italy, Singapore, and Colombia. AESKU.GROUP provides autoimmunity, infectious disease, allergy, and food intolerance testing products to more than 90 countries around the world.


Baker McKenzie's Corporate / M&A team regularly advises big pharma, financial investors and early stage biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised LSP on a $38.5 Million Series B Financing in DNA Script, listed 4SC AG on a capital increase and international private placement, MODAG on a € 12 million Series A Financing, Hitachi Chemical Company, on the take-over of German apceth Biopharma, Forbion as lead investor on a € 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation, Mundipharma on the sale of its Limburg production, CureVac AG on a collaboration with Eli Lilly and Hillhouse Capital as co-investor in the € 50 million Series C cross-over financing of Hookipa Biotech.

Legal advisor to AESKU.GROUP:
Baker McKenzie

Lead: Corporate/M&A: Berthold Hummel (partner, Munich)

International Team: Corporate/M&A: Dr. Katja Heuterkes (counsel, Munich), Dr. Julia Rossié (associate, Munich), Thomas Hughes (partner, Chicago), Brandon Zelasko (associate, Chicago), Aidan Milstead (associate, Chicago)
Tax: Dr. Christoph Becker (partner, Frankfurt), Kai Kramer (partner, Houston), Ross Staine (associate, Houston),
Employment: Christopher Guldberg (partner, Chicago), Andrew Boling (partner, Chicago)

Explore Our Newsroom